Decitabine
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Ruijin Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07493330CT.gov Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | — | Not Yet Recruiting | — | — | — |
NCT05403450CT.gov A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) | — | Active Not Recruiting | — | — | — |
NCT03240211CT.gov Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | — | Active Not Recruiting | — | — | — |
NCT06941688CT.gov Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | Ruijin Hospital | P3 | BB · 64 |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →